Physician profile
Sunil Albert
NPI 1245437367
$10,133.92
in general payments reported to CMS, 2019-2025
45 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,427 · 2020: $997 · 2021: $1,703 · 2022: $734 · 2023: $1,712 · 2024: $1,257 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,133.59 | 2019-2025 | Proclaim |
| Boston Scientific Corporation | $1,111.10 | 2019-2025 | Intracept, General - Pain Management, Superion Indirect Decompression System |
| Vertos Medical, INC. | $1,108.18 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $1,018.39 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $590.76 | 2019-2025 | Belbuca, Xtampza |
| Mml US, INC. | $508.41 | 2023-2025 | Reactiv8 |
| Relievant Medsystems, INC. | $490.13 | 2022-2023 | Intracept |
| Saluda Medical Americas, INC. | $429.54 | 2025 | Evoke |
| Biodelivery Sciences International, INC. | $389.78 | 2020-2021 | |
| Horizon Therapeutics Plc | $319.22 | 2019-2022 | |
| Nalu Medical, INC. | $311.09 | 2023-2024 | Nalu Neurostimulation System |
| Painteq LLC | $273.30 | 2021-2024 | Painteq |
| Nevro Corp. | $243.62 | 2019-2024 | Senza |
| Virtus Pharmaceuticals LLC | $203.67 | 2020-2021 | |
| Stimwave Technologies Incorporated | $198.13 | 2019 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $148.45 | 2021-2022 | |
| Protega Pharmaceutials INC | $140.10 | 2025 | Roxybond |
| Medtronic USA, INC. | $138.15 | 2019-2020 | |
| Si-Bone, INC. | $136.40 | 2019-2024 | |
| Pfizer INC. | $94.63 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $84.17 | 2019-2021 | |
| Valinor Pharma, LLC | $82.72 | 2024-2025 | Movantik |
| Biotronik Nro, INC. | $76.66 | 2025 | Prospera |
| Kowa Pharmaceuticals America, INC. | $75.68 | 2022-2023 | Seglentis |
| Zyla Life Sciences, INC. | $73.53 | 2019-2020 | |
| Radius Health, INC. | $72.67 | 2020-2021 | |
| Allergan, INC. | $63.24 | 2019-2021 | |
| Bioventus LLC | $62.20 | 2019-2021 | |
| Medtronic, INC. | $54.03 | 2022-2023 | Intellis Adaptivestim |
| Daiichi Sankyo INC. | $49.09 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.92 | 2019-2020 | |
| Fidia Pharma USA INC. | $42.04 | 2019-2024 | Hym/Hyn |
| Forte Bio-Pharma LLC | $41.87 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Elutia, INC. | $41.27 | 2019 | |
| Assertio Therapeutics, INC. | $41.25 | 2019-2020 | |
| Abbvie INC. | $37.04 | 2022-2024 | |
| Ibsa Pharma INC. | $36.62 | 2021 | |
| Averitas Pharma INC. | $35.77 | 2023-2024 | Qutenza |
| Baudax Bio INC. | $32.29 | 2020 | |
| Zimmer Biomet Holdings, INC. | $21.27 | 2024 | Visco-3 Sodium Hyaluronate |
| Ultragenyx Pharmaceutical INC. | $18.16 | 2019 | |
| Shionogi INC | $16.79 | 2019 | |
| Depuy Synthes Sales INC. | $16.39 | 2019 | |
| Redhill Biopharma INC. | $13.66 | 2021 | |
| Vertical Pharmaceuticals, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.